ScholarIQanswers from OpenAlex & ORCID
Mark Lebwohl
ResearcherPublications, citations & collaboration network
Mark Lebwohl is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Mark Lebwohl have?
ScholarIQindexed works
Mark Lebwohl has 1,406 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Mark Lebwohl have?
ScholarIQcitation count
Mark Lebwohl has 56,799 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Mark Lebwohl?
ScholarIQh-index
Mark Lebwohl has an h-index of 120 in OpenAlex.
What is the i10-index of Mark Lebwohl?
ScholarIQi10-index
Mark Lebwohl has an i10-index of 555 in OpenAlex.
What is the ORCID of Mark Lebwohl?
ScholarIQorcid
The ORCID for Mark Lebwohl is on the source record.
What is the OpenAlex record for Mark Lebwohl?
ScholarIQopenalex
The OpenAlex for Mark Lebwohl is on the source record.
What are the most-cited papers on Mark Lebwohl?
ScholarIQmost cited works
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Kim Papp, Richard G. Langley, Mark Lebwohl, Gerald G. Krueger, Philippe Szapary, Newman Yeilding, Cynthia Guzzo, Ming-Chun Hsu, Yuhua Wang, Shu Li, Lisa T. Dooley, Kristian Reich
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
Alan Menter, Bruce Strober, Daniel H. Kaplan, Darío Kivelevitch, Elizabeth Farley Prater, Benjamin K. Stoff, April W. Armstrong, Cody Connor, Kelly M. Cordoro, Dawn Marie R. Davis, Boni E. Elewski, Joel M. Gelfand, Kenneth B. Gordon, Alice B. Gottlieb, Arthur Kavanaugh, Matthew Kiselica, Neil J. Korman, Daniela Kroshinsky, Mark Lebwohl, Craig L. Leonardi, Jason Lichten, Henry W. Lim, Nehal N. Mehta, Amy S. Paller, Sylvia L. Parra, Arun L. Pathy, Reena Rupani, Michael Siegel, Emily Wong, Jashin J. Wu, Vidhya Hariharan, Craig A. Elmets
Psoriasis
Jacqueline Greb, Ari M. Goldminz, James T. Elder, Mark Lebwohl, Dafna D. Gladman, Jashin J. Wu, Nehal N. Mehta, A.Y. Finlay, Alice B. Gottlieb
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Mark Lebwohl, Bruce Strober, Alan Menter, Kenneth B. Gordon, Jolanta Węgłowska, L. Puig, Kim Papp, Lynda Spelman, Darryl Toth, Francisco A. Kerdel, April W. Armstrong, Georg Stingl, Alexa B. Kimball, H. Bachelez, Jashin J. Wu, Jeffrey Crowley, Richard G. Langley, Tomasz Blicharski, C. Paul, J.‐P. Lacour, Stephen K. Tyring, Leon Kircik, Sergio Chimenti, Kristina Callis Duffin, Jerry Bagel, John Koo, Gary Aras, Joanne Li, Wenjie Song, Cassandra E. Milmont, Yifei Shi, Ngozi Erondu, Paul Klekotka, Brian L. Kotzin, Ajay Nirula
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
Kenneth B. Gordon, Bruce Strober, Mark Lebwohl, Matthias Augustin, Andrew Blauvelt, Yves Poulin, Kim Papp, Howard Sofen, L. Puig, Peter Foley, Mamitaro Ohtsuki, Mary Flack, Ziqian Geng, Yihua Gu, Joaquin Valdes, Elizabeth H. Thompson, H. Bachelez